On September 25, 2024, GoLiver Therapeutics, a start-up specializing in innovative biotherapies, announced that it was the winner of the “Innovations in biotherapies and bioproduction” call for projects, as part of the France 2030 program. This distinction is accompanied by €1.6 million in funding to support the GOCLINICALS project, an ambitious program aimed at revolutionizing the treatment of serious liver diseases through regenerative medicine.
An innovative treatment for serious liver diseases
GoLiver Therapeutics focuses on developing biomedicines to treat severe liver failure, a condition that is often fatal if not treated in time. Currently, liver transplantation is the only recognized curative solution for these advanced diseases. However, this treatment is limited by the limited number of grafts available and graft-related complications.
The GOCLINICALS project aims to offer a promising alternative with the development of GLTX-001an injectable biomedicine based on liver cells. Designed to regenerate the diseased liver, this innovative treatment could transform the management of acute and chronic liver diseases by replacing transplantation with a more accessible solution. The first clinical stages will aim to demonstrate the tolerance, safety and effectiveness of this treatment.
A breakthrough in cellular bioproduction
The development of cell-based drugs, such as GLTX-001, poses significant challenges in terms of bioproduction. The firm leading the project overcame these obstacles thanks to innovative technology making it possible to produce billions of drug cells in sufficient quantities for clinical use. This platform is based on the use of pluripotent stem cells, which can be differentiated into liver cells. One of the main advantages is its efficiency, as it uses already commercialized bioreactors, which speeds up the production process and reduces costs.
GoLiver Therapeutics collaborates closely with leading partners in the field of cell therapy. Among them, the cell and gene therapy unit (UTCG) of the Nantes University Hospital, with which a GMP pilot batch of 15 billion liver cells has already been produced. The Paul-Brousse hospital of AP-HP, the largest liver transplant center in France, is also a key player in the GOCLINICALS project.
Thanks to this funding from France 2030, GoLiver Therapeutics is on the verge of taking a decisive step in the development of regenerative medicine. According to Tuan Huy Nguyen, President of GoLiver Therapeutics, this support will allow the company to begin clinical trials on patients and confirm the therapeutic potential of GLTX-001. “ The preclinical results are impressive, and the fact that this treatment can be available in unlimited quantities and ready for use is already a considerable advantage.he declares.
Liver disease affects approximately 800 million people worldwide today, and liver failure is responsible for more than two million deaths each year. Despite this global burden, only 30,000 liver transplants are performed each year. Liver regeneration using differentiated stem cells therefore represents a major hope for these patients. GoLiver Therapeutics aims to respond to this urgent medical need by offering an innovative and scalable solution.
Photo credit: Pixabay (cc)
[cc] Breizh-info.com, 2024, dispatches free to copy and distribute subject to mention and link to the original source
